Piper Sandler Maintains Overweight on Perspective Therapeutics, Lowers Price Target to $8
Benzinga Newsdesk 1 hour ago
Analyst RatingsNewsPrice Target
Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $14 to $8.
Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $14 to $8.